Published On: Wed, Sep 25th, 2013

Plandai Biotechnology, Inc. (OTCQB: PLPL) Announces Agreement With Oasix, Inc. to Distribute Phytofare Pheroid Topical Products

Plandai Biotechnology, Inc. (OTCQB: PLPL) and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat many diseases and conditions, announced Tuesday, September 24th, that it has sold an exclusive license to Oasix, Inc., a Canadian-based company that develops skin care products.

The terms of the license is for a five year period, and will be limited to ph2TM Topical Catechin Complex for cosmetic uses in Canada, the US, South Africa and Nigeria.  Under the terms of this exclusive license, Oasix will have the right to develop and market their cosmetic products using Phytofare(TM) Pheroid(TM) Topical Catechin Complex (“ph2TM”), a new topical cream developed using the nano-entrapment technology that has recently been licensed by Plandai.  The payment terms includes an up-front payment of $250,000 with the balance of $250,000 due upon completion of clinical trials – currently underway at North-WestUniversity.  Oasix is also required to purchase annual minimum quantities of ph2TM Topical Catechin Complex from Plandai.

Plandai Biotechnology agreement with Oasix sets the company up with a solid obligation ensuring product sales expected to begin in 2014.

© Copyright 2016 OTC News Magazine. All rights reserved.